Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program (2016-11)

Exact Sciences Corporation logo

Exact Sciences Corporation






Other: Blood Sample Collection

Study type


Funder types




Details and patient eligibility


The primary objective of this study is to establish a control population to assess performance of an investigational diagnostic test targeting lung neoplasms.

Full description

Subjects will be participating in a lung cancer screening program at enrollment. Subjects will have a blood sample collected within 60 days of a low-dose CT scan (LDCT). Subjects with nodules present on the LDCT or subjects with a clean LDCT scheduled for a 12-month follow-up may have another blood draw at 12 months.


1,718 patients




50+ years old


Accepts Healthy Volunteers

Inclusion criteria

Subject is male or female, 50 years of age or older.

Subject meets one of two lung cancer screening criteria below.

  • Subject is a candidate for LDCT lung cancer screening and is scheduled for a baseline LDCT scan. There may be circumstances when a patient cannot have an LDCT scan (e.g., due to insurance issues). In these cases, it is allowable for a patient to have a CT scan in order to meet the inclusion criteria. OR
  • Subject has had previous LDCT scan(s) for lung cancer screening and the most recent LDCT scan prior to enrollment is negative for pulmonary nodules (Lung-RADS category 1, no nodules).
  • Subject understands the study procedures and is able to provide informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.

Exclusion criteria

  • Subjects with pulmonary nodules on the most recent LDCT scan prior to enrollment (Lung-RADS category 1 nodules with specific calcifications such as complete, central, popcorn, concentric rings and fat containing nodules are excluded).
  • Prior history of cancer within the past 5 years except for non-melanoma skin cancer.
  • Prior removal of the lung, excluding percutaneous lung biopsy.
  • Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.

Trial design

1,718 participants in 2 patient groups

Lung Cancer Screening Patients - No Nodules
Subjects in an low dose CT screening program that present no nodules.
Other: Blood Sample Collection
Lung Cancer Screening Patients - Nodules
Subjects in an low dose CT screening program that present nodules. Additional follow-up data will be collected for up to 12 months and an additional blood sample collected
Other: Blood Sample Collection

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems